Reinvigorating the immune system to fight cancer with NM21-1480, a next generation IO drug in clinical development.

Advancing a proprietary pipeline of next generation immunology and immuno-oncology drugs.

Developing the best MATCH for patients through plug & play assembly of novel multispecific biotherapeutics.

numab graphic numab graphic numab graphic numab graphic

Highlights of our tech platform & competitive edge

Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first-generation antibody therapies in terms of potency, stability, effect duration, and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Enabling novel modes of action with favorable benefit-to-risk profiles

We are establishing a proprietary pipeline of differentiated therapeutics by targeting clinically validated pathways with multispecific molecules to create novel mechanisms of action designed to differentiate from standard of care by superior efficacy and favorable safety. Our most advanced program, ND021, exemplifies this strategy by blocking immune-suppressive PD-(L)1 signaling with best-in-class potency and simultaneously triggering 4-1BB-mediated T cell stimulation specifically in the tumor microenvironment. ND021 is currently being evaluated in a Phase 1/2 clinical study.



NM21-1480: A novel tri-specific antibody for oncology
Learn more about its unique mode-of-action

video numab
Latest News
December 14, 2021

Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28

Numab Therapeutics AG and 3SBio Inc. announced today that 3SBio’s…

Numab Therapeutics AG and 3SBio Inc. announced today that 3SBio’s subsidiary Sunshine Guojian exercised its option for an exclusive regional license for the development and commercialization of NM28, a potential best-in-class bivalent mesothelin (MSLN)-targeting CD3 T cell engager.
May 20, 2021

Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

Numab Therapeutics AG today announced the closing of a CHF 100…

Numab Therapeutics AG today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.
January 13, 2021

Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatitis Treatment Option

Numab Therapeutics AG today announced the formation of a global…

Numab Therapeutics AG today announced the formation of a global co-development and regional licensing agreement with Kaken Pharmaceutical for the company’s novel multispecific anti-inflammatory drug candidate NM26-2198, which blocks three key pathways in the pathophysiology of atopic dermatitis. The alliance builds on a collaboration and option agreement established in 2017.
More News

Newsletter Sign Up

Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.